Iloprost infusion by a new device as a portable syringe pump: safety, tolerability and agreement

Main Article Content

Paola Faggioli *
Alba Sciascera
Leopoldo Giani
Antonino Mazzone
(*) Corresponding Author:
Paola Faggioli | paola.granata@pagepress.org

Abstract

Background
Iloprost, prostacyclin (PGI2) analogue, effective in treatment of peripheral arterial disease, secondary Raynaud's phenomenon (RP) to connective tissue disease (CTD), vasculitis, pulmonary hypertension, is usually infused through peristaltic pump, or recently through a flow regulator.

Materials and methods
We tested a new portable syringe pump (Pompa Infonde®, Italfarmaco S.p.A., Cinisello Balsamo, Milano) on 120 patients affected by RP to CTD and cryoglobulinaemia, in iloprost therapy with a flow regulator.

Results
Iloprost infused through portable syringe pump is better tolerated, better appreciated by the patients and nurses and no difference was observed on therapeutic effects, with a lower incidence of side effects statistically significant. Only 3 patients were unable to tolerate the device (2 for changes in pressure and 1 for fear) and shifted to traditional method of iloprost infusion.

Conclusions
Iloprost infusion through the portable syringe Pompa Infonde® appears to be safe, better tolerated, more acceptable and equally effective compared to infusion through a flow regulator.


Downloads month by month

Downloads

Download data is not yet available.

Article Details

Most read articles by the same author(s)